vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and CLARIVATE PLC (CLVT). Click either name above to swap in a different company.
Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($814.3M vs $585.5M, roughly 1.4× CLARIVATE PLC). Amneal Pharmaceuticals, Inc. runs the higher net margin — 4.3% vs -6.9%, a 11.2% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (11.5% vs -1.4%). Amneal Pharmaceuticals, Inc. produced more free cash flow last quarter ($108.5M vs $78.9M). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (11.1% CAGR vs -5.1%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Clarivate Plc is a British-American publicly traded analytics company that operates a collection of subscription-based services, in the areas of bibliometrics and scientometrics; business and market intelligence, and competitive profiling for pharmacy and biotech, patents, and regulatory compliance; trademark protection, and domain and brand protection. Clarivate calculates the impact factor of scientific journals, using data from its Web of Science product family, that also includes services...
AMRX vs CLVT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $814.3M | $585.5M |
| Net Profit | $35.1M | $-40.2M |
| Gross Margin | 36.5% | 67.2% |
| Operating Margin | 13.8% | — |
| Net Margin | 4.3% | -6.9% |
| Revenue YoY | 11.5% | -1.4% |
| Net Profit YoY | 212.9% | -163.1% |
| EPS (diluted) | $0.10 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $585.5M | ||
| Q4 25 | $814.3M | $617.0M | ||
| Q3 25 | $784.5M | $623.1M | ||
| Q2 25 | $724.5M | $621.4M | ||
| Q1 25 | $695.4M | $593.7M | ||
| Q4 24 | $730.5M | $663.0M | ||
| Q3 24 | $702.5M | $622.2M | ||
| Q2 24 | $701.8M | $650.3M |
| Q1 26 | — | $-40.2M | ||
| Q4 25 | $35.1M | $3.1M | ||
| Q3 25 | $2.4M | $-28.3M | ||
| Q2 25 | $22.4M | $-72.0M | ||
| Q1 25 | $12.2M | $-103.9M | ||
| Q4 24 | $-31.1M | $-191.8M | ||
| Q3 24 | $-156.0K | $-65.6M | ||
| Q2 24 | $6.0M | $-304.3M |
| Q1 26 | — | 67.2% | ||
| Q4 25 | 36.5% | 66.8% | ||
| Q3 25 | 34.9% | 65.0% | ||
| Q2 25 | 39.5% | 67.2% | ||
| Q1 25 | 36.8% | 65.1% | ||
| Q4 24 | 36.0% | 65.7% | ||
| Q3 24 | 38.4% | 66.2% | ||
| Q2 24 | 35.6% | 67.2% |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 6.7% | ||
| Q3 25 | 9.0% | 7.1% | ||
| Q2 25 | 15.4% | 1.1% | ||
| Q1 25 | 14.4% | -3.5% | ||
| Q4 24 | 10.4% | -9.4% | ||
| Q3 24 | 12.6% | 3.5% | ||
| Q2 24 | 13.6% | -36.9% |
| Q1 26 | — | -6.9% | ||
| Q4 25 | 4.3% | 0.5% | ||
| Q3 25 | 0.3% | -4.5% | ||
| Q2 25 | 3.1% | -11.6% | ||
| Q1 25 | 1.8% | -17.5% | ||
| Q4 24 | -4.3% | -28.9% | ||
| Q3 24 | -0.0% | -10.5% | ||
| Q2 24 | 0.9% | -46.8% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.10 | $0.00 | ||
| Q3 25 | $0.01 | $-0.04 | ||
| Q2 25 | $0.07 | $-0.11 | ||
| Q1 25 | $0.04 | $-0.15 | ||
| Q4 24 | $-0.10 | $-0.27 | ||
| Q3 24 | $0.00 | $-0.09 | ||
| Q2 24 | $0.02 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.0M | — |
| Total DebtLower is stronger | $2.6B | $4.3B |
| Stockholders' EquityBook value | $-70.8M | $4.8B |
| Total Assets | $3.7B | $10.9B |
| Debt / EquityLower = less leverage | — | 0.89× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $329.2M | ||
| Q3 25 | $201.2M | $318.7M | ||
| Q2 25 | $71.5M | $362.6M | ||
| Q1 25 | $59.2M | $354.0M | ||
| Q4 24 | $110.6M | $295.2M | ||
| Q3 24 | $74.0M | $388.5M | ||
| Q2 24 | $43.8M | $376.4M |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $2.6B | $4.3B | ||
| Q3 25 | $2.6B | $4.4B | ||
| Q2 25 | $2.2B | $4.5B | ||
| Q1 25 | $2.2B | $4.5B | ||
| Q4 24 | $2.4B | $4.5B | ||
| Q3 24 | $2.4B | $4.6B | ||
| Q2 24 | $2.4B | $4.6B |
| Q1 26 | — | $4.8B | ||
| Q4 25 | $-70.8M | $4.8B | ||
| Q3 25 | $-109.5M | $4.9B | ||
| Q2 25 | $-112.1M | $5.0B | ||
| Q1 25 | $-131.7M | $5.0B | ||
| Q4 24 | $-109.3M | $5.1B | ||
| Q3 24 | $-93.4M | $5.5B | ||
| Q2 24 | $-57.5M | $5.6B |
| Q1 26 | — | $10.9B | ||
| Q4 25 | $3.7B | $11.1B | ||
| Q3 25 | $3.6B | $11.2B | ||
| Q2 25 | $3.4B | $11.4B | ||
| Q1 25 | $3.4B | $11.5B | ||
| Q4 24 | $3.5B | $11.5B | ||
| Q3 24 | $3.5B | $12.0B | ||
| Q2 24 | $3.5B | $12.1B |
| Q1 26 | — | 0.89× | ||
| Q4 25 | — | 0.89× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.3M | $134.7M |
| Free Cash FlowOCF − Capex | $108.5M | $78.9M |
| FCF MarginFCF / Revenue | 13.3% | 13.5% |
| Capex IntensityCapex / Revenue | 2.7% | 9.5% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $269.9M | $333.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $134.7M | ||
| Q4 25 | $130.3M | $159.9M | ||
| Q3 25 | $118.5M | $181.1M | ||
| Q2 25 | $83.8M | $116.3M | ||
| Q1 25 | $7.4M | $171.2M | ||
| Q4 24 | $118.1M | $141.3M | ||
| Q3 24 | $141.8M | $202.9M | ||
| Q2 24 | $39.7M | $126.2M |
| Q1 26 | — | $78.9M | ||
| Q4 25 | $108.5M | $89.2M | ||
| Q3 25 | $106.2M | $115.5M | ||
| Q2 25 | $61.0M | $50.3M | ||
| Q1 25 | $-5.8M | $110.3M | ||
| Q4 24 | $102.9M | $59.1M | ||
| Q3 24 | $124.8M | $126.3M | ||
| Q2 24 | $29.0M | $60.3M |
| Q1 26 | — | 13.5% | ||
| Q4 25 | 13.3% | 14.5% | ||
| Q3 25 | 13.5% | 18.5% | ||
| Q2 25 | 8.4% | 8.1% | ||
| Q1 25 | -0.8% | 18.6% | ||
| Q4 24 | 14.1% | 8.9% | ||
| Q3 24 | 17.8% | 20.3% | ||
| Q2 24 | 4.1% | 9.3% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 2.7% | 11.5% | ||
| Q3 25 | 1.6% | 10.5% | ||
| Q2 25 | 3.2% | 10.6% | ||
| Q1 25 | 1.9% | 10.3% | ||
| Q4 24 | 2.1% | 12.4% | ||
| Q3 24 | 2.4% | 12.3% | ||
| Q2 24 | 1.5% | 10.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 51.58× | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
